These 2 Penny Stocks Could Quadruple (Or More), Says H.C. Wainwright, , on October 6, 2020 at 7:30 pm

By
On October 6, 2020
Tags:

Out on Wall Street, one group of stocks divides investors into either fans or critics. Penny stocks, or tickers that trade for less than $5 per share, are known for stirring up mixed reactions among market watchers, as these names are unrivaled in terms of both their risk and reward potential.Some argue the bargain prices are just too good to be true, noting that there could be a very legitimate reason they are trading at such low levels. Problems like weak fundamentals or overwhelming headwinds come to mind here.However, the more risk-tolerant see the possibility of colossal returns as too enticing to ignore. With these stocks, you get more bang for your buck. Additionally, given the lower price tags, even minor share price appreciation can translate to massive percentage gains.Taking this into account, we turned to the pros from investment firm H.C. Wainwright for some inspiration. Looking at two penny stocks with the H.C. Wainwright stamp of approval, the firm’s top analysts believe both could quadruple, or more, in the next year.Running the tickers through TipRanks’ database, we wanted to find out what makes both names so compelling even with the risk involved.ObsEva SA (OBSV)Hoping to usher in a new era in women’s reproductive health, ObsEva works to bring the products women need to market. Currently going for $2.5 apiece, H.C. Wainwright thinks that the share price presents an attractive entry point.Representing the firm, 5-star analyst Raghuram Selvaraju points out that pivotal data for linzagolix, the company’s lead candidate, in uterine fibroids appears “best-in-class.” Linzagolix is an orally administered gonadotropin-releasing hormone (GnRH) receptor antagonist that could potentially provide effective management of endometriosis-associated pain while mitigating bone mineral density loss and other adverse effects typically associated with the currently approved treatment.Looking at the data from the pivotal trials of the therapy, PRIMROSE 1 and PRIMROSE 2, the former met the primary endpoint at 24 weeks, demonstrating that women receiving linzagolix experienced a statistically significant and clinically meaningful reduction in menstrual blood loss compared to placebo. Additionally, patients that received the 200mg dose of linzagolix with add-back therapy (ABT) achieved a 75.5% responder rate and those receiving the 100mg dose of linzagolix without ABT achieved a 56.4% responder rate.As for PRIMROSE-2, longer-term data revealed that continued treatment with linzagolix for 52 weeks provided sustained efficacy, with the drug also well-tolerated. Responder rates of 91.6% and 53.2% were observed in women receiving 200mg with ABT and 100mg without ABT, respectively, both of which are similar to the responder rates observed at week 24 of the study. Weighing in on this result, Selvaraju stated, “This underscores the durability of the efficacy achieved with linzagolix.”Given that both studies saw women receiving linzagolix experience statistically significant improvements across a number of clinically relevant secondary endpoints, including reduction in pain, improvement in anemia and quality of life, Selvaraju has high hopes.“From our vantage point, linzagolix appears to have best-in-class potency among the clinical-stage gonadotropin-releasing hormone (GnRH) receptor antagonists, along with the ability to be deployed without ABT. Thus, we continue to see it as a best-in-class drug,” the analyst opined.On top of this, Selvaraju highlights the Phase 3 EDELWEISS trials evaluating linzagolix, with the data readout set for next year, in endometriosis as another area to watch. “Positive data for relugolix from Myovant Sciences in the SPIRIT Phase 3 trials appear to have reduced the risk profile of linzagolix in treating endometriosis-associated pain. Relugolix met both co-primary endpoints in each of the SPIRIT studies. We remain confident that linzagolix could be an even more effective GnRH receptor antagonist than relugolix, with the added edge of utility without add-back therapy (ABT),” he said.To this end, Selvaraju rates OBSV a Buy along with a $23 price target. Should this target be met, a twelve-month gain of 812% could be in store. (To watch Selvaraju’s track record, click here)Do other analysts agree with Selvaraju? As it turns out, most do. 3 Buy ratings and a single Hold add up to a Strong Buy analyst consensus. At $15.75, the average price target indicates 535% upside potential from current levels. (See ObsEva stock analysis on TipRanks)Galectin Therapeutics (GALT)Using its unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function, Galectin Therapeutics develops new therapies to improve the lives of patients with chronic liver and skin diseases as well as cancer. While H.C. Wainwright says investors need patience when it comes to this name, which changes hands for $2.70 a share, the firm sees it as a long-term winner.On September 29, the company provided more detail on its NASH-RX Phase 2b/3 trial evaluating its galectin-3 inhibitor candidate, belapectin (GR-MD-02), designed for the treatment of NASH cirrhosis patients who have clinical signs of portal hypertension (PH) and are at risk of developing esophageal varices. It should be noted that GALT is one of the few companies with a late clinical stage candidate for NASH cirrhosis, and NASH-RX is the first and only pivotal program for the cirrhotic NASH population.NASH-RX evaluates two belapectin doses versus placebo in about 315 NASH patients in its Phase 2b portion. In addition, following a pre-specified interim analysis (IA) conducted by the trial’s Data Monitoring Committee (DMC) when all patients in the Phase 2b portion have completed at least 78 weeks of treatment and underwent a gastroesophageal endoscopic (EGD) assessment, belapectin could either be eligible for accelerated approval if the primary endpoint of reduced incidence of new varices is achieved, or advance into a Phase 3 portion with an optimal belapectin dose enrolling an additional 210 patients.Covering the stock for H.C. Wainwright, 5-star analyst Ed Arce noted: “For the Phase 3 portion, Galectin could choose to implement adaptations including sample size and randomization ratio adjustments, inclusion/exclusion criteria changes, and to incorporate results of a separate hepatic impairment study. Therefore, NASH-RX has two shots on goal for success, with the interim analysis of the Phase 2b portion that is expected in Q2 2023 as its first shot on goal.”When it comes to the available clinical data, top-line results from the Phase 2b NASH-CX study demonstrated a statistically significant and clinically meaningful reduction in the absolute change of the hepatic venous pressure gradient (HVPG) at 54 weeks within a patient subset, without varices at baseline, who were treated with belapectin 2mg/kg. Arce believes it’s encouraging that no patients in this NASH-CX patient subset reported the formation of new varices, compared to 18% of patients in the placebo group.Expounding on this, Arce stated, “We note that patients with no baseline varices represented approximately 50% of the total NASH-CX study population, and is now an entry criteria for the NASH-RX study… While this subset analysis represents a small patient sample size, it nonetheless provides the early clinical rationale to support belapectin’s entry into the NASH-RX trial with a specific patient population.” He added, “We continue to believe in belapectin’s potential in NASH cirrhosis.”Taking all of this into consideration, Arce maintains a Buy rating and $12 price target. This target conveys his confidence in GALT’s ability to climb 358% higher in the next year. (To watch Arce’s track record, click here)Turning to the rest of the Street, it has been quiet with respect to other analyst activity. As Arce is the only analyst that has thrown an opinion into the mix over the last three months, GALT is a Moderate Buy. (See GALT stock analysis on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.,

These 2 Penny Stocks Could Quadruple (Or More), Says H.C. WainwrightOut on Wall Street, one group of stocks divides investors into either fans or critics. Penny stocks, or tickers that trade for less than $5 per share, are known for stirring up mixed reactions among market watchers, as these names are unrivaled in terms of both their risk and reward potential.Some argue the bargain prices are just too good to be true, noting that there could be a very legitimate reason they are trading at such low levels. Problems like weak fundamentals or overwhelming headwinds come to mind here.However, the more risk-tolerant see the possibility of colossal returns as too enticing to ignore. With these stocks, you get more bang for your buck. Additionally, given the lower price tags, even minor share price appreciation can translate to massive percentage gains.Taking this into account, we turned to the pros from investment firm H.C. Wainwright for some inspiration. Looking at two penny stocks with the H.C. Wainwright stamp of approval, the firm’s top analysts believe both could quadruple, or more, in the next year.Running the tickers through TipRanks’ database, we wanted to find out what makes both names so compelling even with the risk involved.ObsEva SA (OBSV)Hoping to usher in a new era in women’s reproductive health, ObsEva works to bring the products women need to market. Currently going for $2.5 apiece, H.C. Wainwright thinks that the share price presents an attractive entry point.Representing the firm, 5-star analyst Raghuram Selvaraju points out that pivotal data for linzagolix, the company’s lead candidate, in uterine fibroids appears “best-in-class.” Linzagolix is an orally administered gonadotropin-releasing hormone (GnRH) receptor antagonist that could potentially provide effective management of endometriosis-associated pain while mitigating bone mineral density loss and other adverse effects typically associated with the currently approved treatment.Looking at the data from the pivotal trials of the therapy, PRIMROSE 1 and PRIMROSE 2, the former met the primary endpoint at 24 weeks, demonstrating that women receiving linzagolix experienced a statistically significant and clinically meaningful reduction in menstrual blood loss compared to placebo. Additionally, patients that received the 200mg dose of linzagolix with add-back therapy (ABT) achieved a 75.5% responder rate and those receiving the 100mg dose of linzagolix without ABT achieved a 56.4% responder rate.As for PRIMROSE-2, longer-term data revealed that continued treatment with linzagolix for 52 weeks provided sustained efficacy, with the drug also well-tolerated. Responder rates of 91.6% and 53.2% were observed in women receiving 200mg with ABT and 100mg without ABT, respectively, both of which are similar to the responder rates observed at week 24 of the study. Weighing in on this result, Selvaraju stated, “This underscores the durability of the efficacy achieved with linzagolix.”Given that both studies saw women receiving linzagolix experience statistically significant improvements across a number of clinically relevant secondary endpoints, including reduction in pain, improvement in anemia and quality of life, Selvaraju has high hopes.“From our vantage point, linzagolix appears to have best-in-class potency among the clinical-stage gonadotropin-releasing hormone (GnRH) receptor antagonists, along with the ability to be deployed without ABT. Thus, we continue to see it as a best-in-class drug,” the analyst opined.On top of this, Selvaraju highlights the Phase 3 EDELWEISS trials evaluating linzagolix, with the data readout set for next year, in endometriosis as another area to watch. “Positive data for relugolix from Myovant Sciences in the SPIRIT Phase 3 trials appear to have reduced the risk profile of linzagolix in treating endometriosis-associated pain. Relugolix met both co-primary endpoints in each of the SPIRIT studies. We remain confident that linzagolix could be an even more effective GnRH receptor antagonist than relugolix, with the added edge of utility without add-back therapy (ABT),” he said.To this end, Selvaraju rates OBSV a Buy along with a $23 price target. Should this target be met, a twelve-month gain of 812% could be in store. (To watch Selvaraju’s track record, click here)Do other analysts agree with Selvaraju? As it turns out, most do. 3 Buy ratings and a single Hold add up to a Strong Buy analyst consensus. At $15.75, the average price target indicates 535% upside potential from current levels. (See ObsEva stock analysis on TipRanks)Galectin Therapeutics (GALT)Using its unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function, Galectin Therapeutics develops new therapies to improve the lives of patients with chronic liver and skin diseases as well as cancer. While H.C. Wainwright says investors need patience when it comes to this name, which changes hands for $2.70 a share, the firm sees it as a long-term winner.On September 29, the company provided more detail on its NASH-RX Phase 2b/3 trial evaluating its galectin-3 inhibitor candidate, belapectin (GR-MD-02), designed for the treatment of NASH cirrhosis patients who have clinical signs of portal hypertension (PH) and are at risk of developing esophageal varices. It should be noted that GALT is one of the few companies with a late clinical stage candidate for NASH cirrhosis, and NASH-RX is the first and only pivotal program for the cirrhotic NASH population.NASH-RX evaluates two belapectin doses versus placebo in about 315 NASH patients in its Phase 2b portion. In addition, following a pre-specified interim analysis (IA) conducted by the trial’s Data Monitoring Committee (DMC) when all patients in the Phase 2b portion have completed at least 78 weeks of treatment and underwent a gastroesophageal endoscopic (EGD) assessment, belapectin could either be eligible for accelerated approval if the primary endpoint of reduced incidence of new varices is achieved, or advance into a Phase 3 portion with an optimal belapectin dose enrolling an additional 210 patients.Covering the stock for H.C. Wainwright, 5-star analyst Ed Arce noted: “For the Phase 3 portion, Galectin could choose to implement adaptations including sample size and randomization ratio adjustments, inclusion/exclusion criteria changes, and to incorporate results of a separate hepatic impairment study. Therefore, NASH-RX has two shots on goal for success, with the interim analysis of the Phase 2b portion that is expected in Q2 2023 as its first shot on goal.”When it comes to the available clinical data, top-line results from the Phase 2b NASH-CX study demonstrated a statistically significant and clinically meaningful reduction in the absolute change of the hepatic venous pressure gradient (HVPG) at 54 weeks within a patient subset, without varices at baseline, who were treated with belapectin 2mg/kg. Arce believes it’s encouraging that no patients in this NASH-CX patient subset reported the formation of new varices, compared to 18% of patients in the placebo group.Expounding on this, Arce stated, “We note that patients with no baseline varices represented approximately 50% of the total NASH-CX study population, and is now an entry criteria for the NASH-RX study… While this subset analysis represents a small patient sample size, it nonetheless provides the early clinical rationale to support belapectin’s entry into the NASH-RX trial with a specific patient population.” He added, “We continue to believe in belapectin’s potential in NASH cirrhosis.”Taking all of this into consideration, Arce maintains a Buy rating and $12 price target. This target conveys his confidence in GALT’s ability to climb 358% higher in the next year. (To watch Arce’s track record, click here)Turning to the rest of the Street, it has been quiet with respect to other analyst activity. As Arce is the only analyst that has thrown an opinion into the mix over the last three months, GALT is a Moderate Buy. (See GALT stock analysis on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road
#12-01 Capital Tower
Singapore 068912

New York

Coming Soon!

Dubai

Coming Soon!

Market Coverage